Aharon Schwartz
Known title: DirectorCIK: 0001625184
Aharon Schwartz's purchase track record
Aharon Schwartz has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/10/2025 | PLX | $206K | +8.9% | +10.8% | +13.3% |
| 1/3/2023 | PLX | $156K | +59.9% | +31.4% | +16.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PLX | ▲ Buy | Grant | 7,500 | — | 9/3/2025 | View on chart |
| PLX | ▲ Buy | Open Market | 129,000 | $206K | 6/10/2025 | View on chart |
| PLX | ▲ Buy | Open Market | 110,000 | $156K | 1/3/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
PLX: No direct news; broader market analyst moves noted
Recent news coverage focuses on analyst actions for other companies like Netflix and SanDisk, with no specific updates reported for Protalix BioTherapeutics. The stock currently trades within its 52-week range of $1.60 to $3.19, holding above the identified support level of $2.31. While technical signals show some divergence, the lack of company-specific headlines keeps the immediate news impact low.
PLX: No direct news; broader market analyst moves noted. Recent news coverage focuses on analyst actions for other companies like Netflix and SanDisk, with no specific updates reported for Protalix BioTherapeutics. The stock currently trades within its 52-week range of $1.60 to $3.19, holding above the identified support level of $2.31. While technical signals show some divergence, the lack of company-specific headlines keeps the immediate news impact low.